Modi Govt to Study China, US and EU Drug Pricing Policies to Make Medicine Affordable in India – Community News
Us China

Modi Govt to Study China, US and EU Drug Pricing Policies to Make Medicine Affordable in India

To make drugs accessible and affordable in India, Narendra Modi’s government plans to launch an investigation into drug pricing policies in at least 10 countries, including China, Sri Lanka, Bangladesh and the United States, reported. heard. The Department of Pharmaceuticals (DoP) – under the union ministry of chemicals and fertilizers – has launched a tender to find a reputable company that can conduct the study on behalf of the government.

The aim of the study is to understand the drug pricing methodology applied in the international market covering at least 10 countries. It also aims to understand lessons learned or best practices from different countries (or regions) in terms of drug availability and affordability.

NPPA at the helm

According to the Request for Proposal (RFP) document labeled “Notice Inviting Tenders,” which was consulted by, the National Pharmaceuticals Pricing Authority (NPPA), the drug price watchdog, wants to engage reputable companies or research institutions to carry out of an investigation. NPPA is part of the DoP.

The title of the paper reads: “Studying the drug pricing policies of different countries/regions and the lessons learned from these countries/regions in terms of access to medicines at affordable prices”.

The deadline to submit the proposal is February 21, the document states, while the nominated bidders will be called for presentation on March 1.

Study will involve secondary sources, top 10 selected countries

According to the document, the government plans to study the regulatory policies or framework for drug pricing of at least 10 countries (or regions) to identify best practices or lessons learned. It also plans to study the operational implementation of drug pricing policies in different countries, in addition to studying other policy aspects that affect drug availability and affordability in these countries.

The minimum 10 countries/regions to be covered are Sri Lanka, Bangladesh, China, EU, UK, Australia, US, Brazil, South Africa and Thailand.

The research will be based primarily on secondary data sources and other information available in the public domain. It also includes interviews or focus group discussions (FGDs) with foreign missions, relevant trade and industry associations, drug exporters, foreign manufacturers to get their feedback or opinion.

According to the 18-page RFP document, the final report must be submitted within four months after the selection of the company. In addition, progress is submitted quarterly by the applicant until the final submission of the report.

Read all the Latest News, Breaking News and Coronavirus News here.

About the author


Add Comment

Click here to post a comment